Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Income from Continuing Operations (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Income from Continuing Operations for 6 consecutive years, with 31946000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 58.02% to 31946000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 113625000.0, a 64.69% decrease, with the full-year FY2025 number at 113625000.0, down 64.69% from a year prior.
  • Income from Continuing Operations was 31946000.0 for Q4 2025 at Janux Therapeutics, down from 24313000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 2284000.0 in Q1 2021 to a low of 33858000.0 in Q2 2025.
  • A 5-year average of 16832150.0 and a median of 16380500.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 757.17% in 2021, then soared 65.96% in 2024.
  • Janux Therapeutics' Income from Continuing Operations stood at 13416000.0 in 2021, then decreased by 19.75% to 16065000.0 in 2022, then increased by 26.81% to 11758000.0 in 2023, then tumbled by 71.93% to 20216000.0 in 2024, then plummeted by 58.02% to 31946000.0 in 2025.
  • Per Business Quant, the three most recent readings for JANX's Income from Continuing Operations are 31946000.0 (Q4 2025), 24313000.0 (Q3 2025), and 33858000.0 (Q2 2025).